Will Opus Genetics stock go up?

According to Danelfin AI, Opus Genetics has today an AI Score of 2/10 (Strong Sell rating), because its probability of beating the market in 3 months (43.86%) is -6.95% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for Opus Genetics stock?

The Opus Genetics target price is $11.18 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold Opus Genetics stock right now?

Opus Genetics has today a Strong Sell rating (AI Score 2/10), according to Danelfin AI. Its probability of beating the market in 3 months (43.86%) is -6.95% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether Opus Genetics stock is a good buy .

Is Opus Genetics undervalued right now?

Based on analysts, the average price target upside for Opus Genetics is +166.25% (1Y). According to Danelfin AI, Opus Genetics has today an AI Score of 2/10 (Strong Sell Rating).

What was the price range of Opus Genetics stock over the past 12 months?

The Opus Genetics stock price range over the past 12 months has been $0.91 - $5.75.

What is going on with Opus Genetics stock in the last 3 months?

The Opus Genetics stock performance in the last quarter has been -7.69%.

Does Opus Genetics offer dividend payments?

No, Opus Genetics does not currently pay dividends.

What is the current market capitalization of Opus Genetics?

Opus Genetics's market cap is $345.13M, as of 2026-07-02 08:00.

When is the next IRD earnings report date?

IRD will publish its next earnings report on 2026-05-12.

Opus Genetics Inc (IRD) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

IRD AI-Powered Stock Analysis

AI Score Explanation

AI Score

Strong Sell

Fundamental
Technical
Sentiment
Low Risk

According to Danelfin’s proprietary AI model, Opus Genetics Inc today receives an AI Score of 2/10, which translates to a Sell rating. The stock has a 44% probability of outperforming the market in the next 3 months, which is 7% lower than the average probability of any stock (51%). The top positive contributor is Operating Cash Flow (Qtr Discrete) (impact +1.15%), which boosts the probability despite being in the bottom 20% of stocks. Alpha 1Y also adds +0.27% and ranks in the top 10%. However, the strongest detractors include Chart Pattern (504d) (impact -2.06%), Gross Margin (impact -1.11%, despite being in the top 10%), and Long-Term Debt Coverage Ratio (impact -0.81%, in the bottom 10%). Other negative signals include Fear & Greed Index (impact -0.73%, value 31 indicating fear), Chart Pattern (120d) (impact -0.69%), and Performance (YTD) (impact -0.40%, in the top 10%). Notable data points include a Gross Margin of 100% (top 10%), yet it detracts from the probability, suggesting the market may view this as unsustainable. Operating Profit Margin is deeply negative at -665.9% (bottom 10%), and Tangible Shareholders' Equity is -$45.8M (bottom 20%), indicating weak financial health. Maximum Volatility is 7.46% (top 30%), reflecting high risk. On the positive side, Alpha 1Y of 3.25 (top 10%) shows strong risk-adjusted returns. Overall, the preponderance of negative signals, especially from technical patterns and weak fundamentals, outweighs the few positive contributors, resulting in a low AI Score and a Sell rating.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Earnings Quality+1.15%
Stability and reliability of reported earnings
Size & Liquidity+0.23%
Company size and trading liquidity

Momentum-3.57%
Direction and strength of recent price movements
Profitability-1.37%
Profitability and operating efficiency metrics
Valuation-1.12%
How the stock is priced relative to its fundamentals
Financial Strength-1.01%
Balance sheet strength and financial resilience
Sentiment-0.95%
How analysts and the market view the stock
Volatility-0.32%
How much the stock price tends to fluctuate

IRD probability advantage of beating the market (3M):

-6.95%

AI Score

Strong Sell

Opus Genetics (IRD) has an AI Score of 2/10 (Strong Sell) because, according to an overall analysis, it has a probability advantage of -6.95% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.82%) and the probability of IRD (43.86%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any US-listed stock of beating the market (3M)50.82%
IRD probability advantage of beating the market (3M)-6.95%
IRD probability of beating the market (3M)43.86%

IRD probability advantage of beating the market (3M): -6.95%

The AI-powered overall analysis of Opus Genetics (IRD) is based on the 28 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of IRD:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Technical	Chart Pattern (504d)	figure_42	N/A	-2.06%
Fundamental	Operating Cash Flow (Qtr Discrete)	-12.73		+1.15%
Fundamental	Gross Margin	100		-1.11%
Fundamental	Long-Term Debt Coverage Ratio	-11.92	N/A	-0.81%
Sentiment	Fear & Greed Index (CNN)	31	N/A	-0.73%
Technical	Chart Pattern (120d)	figure_123	N/A	-0.69%
Technical	Performance (YTD)	1.09%		-0.40%
Fundamental	Net Property, Plant & Equipment (Net PP&E)	0.19	N/A	-0.32%
Technical	Maximum Volatility	7.46%		-0.32%
Fundamental	Tangible Shareholders' Equity	-45.84		-0.29%
Technical	Upgrade to unlock			+0.27%
Technical	Upgrade to unlock			-0.26%
Fundamental	Upgrade to unlock			-0.26%
Sentiment	Upgrade to unlock			-0.26%
Fundamental	Upgrade to unlock			-0.26%

Rest of Alpha Signals: -0.60%

IRD probability advantage of beating the market (3M)Total:-6.95%
IRD AI Score

Significant changes Vs previous day

IRD Short Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$4.20
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro)
Take Profit:$XXXXXPro (XXXXX
Pro
)

IRD Proven Sell Signal & Price Forecast

This is the price chart for IRD from January 1, 2026 until today. The chart indicates, in red, the 61 days when the stock received a Sell/Strong Sell rating (sell signals, AI Score 1 to 3).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Sell signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Sell signals

Forecast:

1 Month
3 Months
6 Months
1 Year

IRD Average Past Performance & Loss Rate

Three months after its 967 Sell signals since July 2026, IRD had an average performance of xxxxxx and a xxxxxx Loss rate (negative performance).

967 Past IRD Sell Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				-36.83%
Average Alpha				-55.72%
Loss Rate (% Negative Perf.)				84.18%
% Negative Alpha				92.59%

IRD Frequently Asked Questions

Will Opus Genetics stock go up?
According to Danelfin AI, Opus Genetics has today an AI Score of 2/10 (Strong Sell rating), because its probability of beating the market in 3 months (43.86%) is -6.95% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for Opus Genetics stock?
Is it a good time to buy, sell, or hold Opus Genetics stock right now?
Is Opus Genetics undervalued right now?
What was the price range of Opus Genetics stock over the past 12 months?
What is going on with Opus Genetics stock in the last 3 months?
Does Opus Genetics offer dividend payments?
What is the current market capitalization of Opus Genetics?
When is the next IRD earnings report date?

Opus Genetics Inc Company Profile

Opus Genetics Inc (IRD) is a biotechnology company focused on developing gene therapies for rare inherited retinal diseases. The company aims to address unmet medical needs for patients suffering from conditions that lead to vision loss and blindness. Its primary customers are patients and healthcare providers involved in treating these specific genetic disorders.

Opus Genetics is advancing a pipeline of gene therapy candidates. These therapies are designed to deliver functional genes to retinal cells, potentially restoring or preserving vision. The company's core focus is on genetic eye diseases with a clear genetic cause and a significant impact on patients' lives.

Key therapeutic areas include diseases like X-linked retinitis pigmentosa (XLRP) and other inherited retinal degenerations. The company is developing treatments that target specific genetic mutations responsible for these conditions. Its approach involves utilizing viral vectors to deliver therapeutic genetic material directly to the affected cells in the eye.

Opus Genetics generates revenue through the development and potential commercialization of its gene therapy products. The company's go-to-market strategy will involve direct engagement with the medical community and partnerships with pharmaceutical distributors. Its reach is global, aiming to serve patients worldwide.

Sector:
Country:United States
Industry:
Address:8 Davis Drive, Suite 220, Durham
Employees:28
Website:opusgtx.com

Pros

Intellectual property protection for novel gene therapies

Regulatory exclusivity for orphan drug designations

High pricing power for therapies addressing unmet needs

Platform technology scalability across multiple indications

Lack of alternative treatments for specific genetic conditions

Cons

Extensive capital requirements for clinical development

Long and uncertain regulatory approval pathways

High risk of clinical trial failures

Limited patient populations for ultra-rare diseases

Reimbursement challenges for high-cost treatments

Company	AI Score	Compare
OCGNOcugen Inc
MGTXMeiraGTx Holdings PLC
OCULOcular Therapeutix Inc
RAREUltragenyx Pharmaceutical Inc
RGNXRegenxbio Inc

Company	AI Score	Compare
OCGNOcugen Inc
MGTXMeiraGTx Holdings PLC
OCULOcular Therapeutix Inc
RAREUltragenyx Pharmaceutical Inc
RGNXRegenxbio Inc

IRD Stock AI Analysis